Refine your search with our Advanced Search Tool
Listing contains 128 trial(s)
Bladder Cancer
Lab
Use of Urinary Nuclear Matrix Protein BLCA-4 LevelsiIn the Diagnosis of Bladder Cancer Study Number: 00-006 |
Phase II
Phase II Study of Docetaxel and Oxaliplatin in Metastatic Transitional Cell Cancer (TCC) of the Urothelial Tract Study Number: 04-055 |
Kidney (Renal Cell) Cancer
Phase III
A Randomized Double Blind Phase III Trial of Adjuvant Sunitinib vs. Sorafenib vs. Placebo in Patients with Resected Renal Cell Carcinoma Study Number: 06-064 |
Prostate Cancer
Phase II
Phase II Trial of Thalidomide and Doxil (Doxorubicin HCL Liposome Injection) in Patients with Androgen Independent Prostate Cancer (AIPC) with Rising PSA While on Chemotherapy Study Number: 05-078 |
A Randomized, Phse II Study of GW786034 (Pazopanib) in Stage DO Relapsed Androgen Sensitive Prostate Cancer Following Limited GnRH Agonist Therapy Study Number: 06-135 |
Dosimetric and Morbidity Outcomes of Cs-131 Brachytherapy Combination with External Beam Radiation Therapy in Subjects with Intermediate to High Risk Adenocarcinoma of the Prostate: An Observational Study Study Number: 08-007 |
IMCL CP18-0601 A Phase 2, Multicenter, Randomized Study of IMC-A12 or IMC-1121B Plus Mitoxantrone and Prednisone in Metastatic Androgen Independent Prostate Cancer (AIPC) Following Disease Progression on Docetaxel-Based Chemotherapy Study Number: 08-069 |
Phase III
Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy vs. Immediate Radical Prostatectomy in Patients with High Risk, Clinically Localized Prostate Cancer Study Number: 07-032 |
A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate only Radiotherapy (SPORT) in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy Study Number: 08-012 |
A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 10 mg ZD4054 in Combination with Docetaxel in Comparison with Docetaxel in Patients with Metastatic Hormone-resistant Prostate Cancer Study Number: 08-037 |
A Phase III, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 10 mg in Non-Metastatic Hormone-resistant Prostate Cancer Patients Study Number: 08-005 |
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF SUNITINIB PLUS PREDNISONE VERSUS PREDNISONE IN PATIENTS WITH PROGRESSIVE METASTATIC HORMONE-REFRACTORY PROSTATE CANCER AFTER FAILURE OF A DOCETAXEL-BASED CHEMOTHERAPY REGIMEN A6181120 - 1125 Study Number: 08-098 |
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined with Dasatinib to Docetaxel Combined with Placebo in Castration-Resistant Prostate Cancer Study Number: 08-118 |
A Phase 3, randomized, double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Cancer Study Number: 09-019 |
Tissue and/or blood banking study
Tissue, Serum, and Urine Banking for the University of Pittsburgh Breast and Prostate Cancer Tissue Bank Study Number: 97-130 |
